Literature DB >> 28825135

Tumor response assessment: comparison between unstructured free text reporting in routine clinical workflow and computer-aided evaluation based on RECIST 1.1 criteria.

Juliane Goebel1, Julia Hoischen2, Carolin Gramsch3, Haemi P Schemuth4, Andreas-Claudius Hoffmann5, Lale Umutlu4, Kai Nassenstein4.   

Abstract

PURPOSE: Standardized computer-aided tumor response assessment is common in clinical trials. In contrast, unstructured free text reporting (UFTR) is common in daily routine. Therefore, this study aimed to discern and quantify differences between UFTR and computer-aided standardized tumor response evaluation based on RECIST 1.1 criteria (RECIST), serving as gold standard, in clinical workflow.
METHODS: One-hundred consecutive patients with cancer eligible for RECIST 1.1 evaluation, who received five follow-up CTs of the trunk, were retrospectively included. All UFTRs were assigned to RECIST response categories [complete response, partial response (PR), stable disease (SD), progressive disease (PD)]. All CTs were re-evaluated using dedicated software (mint lesion™) applying RECIST 1.1. The accordance in tumor response ratings was analyzed using Cohen's kappa.
RESULTS: At the first follow-up, 47 cases were rated differently with an SD underrepresentation and a PR and PD overrepresentation in UFTR. In the subsequent follow-ups, categorical differences were seen in 38, 44, 37, and 44%. Accordance between UFTR and RECIST was fair to moderate (Cohen's kappa: 0.356, 0.477, 0.390, 0.475, 0.376; always p < 0.001). Differences were mainly caused by the rating of even small tumor burden changes as PD or PR in UFTR or by comparison to the most recent prior CT scan in UFTR instead of comparison to nadir or baseline.
CONCLUSIONS: Significant differences in tumor response ratings were detected comparing UFTR and computer-aided standardized evaluation based on RECIST 1.1. Thus, standardized reporting should be implemented in daily routine workflow.

Entities:  

Keywords:  Cross-sectional imaging; Oncologic imaging; RECIST 1.1 criteria; Radiological tumor response assessment; Solid tumors

Mesh:

Year:  2017        PMID: 28825135     DOI: 10.1007/s00432-017-2488-1

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  14 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  Quantitative Radiology Reporting in Oncology: Survey of Oncologists and Radiologists.

Authors:  Les R Folio; Chelsye J Nelson; Menashe Benjamin; Ayelet Ran; Guy Engelhard; David A Bluemke
Journal:  AJR Am J Roentgenol       Date:  2015-09       Impact factor: 3.959

Review 3.  Response criteria in oncologic imaging: review of traditional and new criteria.

Authors:  Temel Tirkes; Margaret A Hollar; Mark Tann; Marc D Kohli; Fatih Akisik; Kumaresan Sandrasegaran
Journal:  Radiographics       Date:  2013 Sep-Oct       Impact factor: 5.333

Review 4.  RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group.

Authors:  Lawrence H Schwartz; Lesley Seymour; Saskia Litière; Robert Ford; Stephen Gwyther; Sumithra Mandrekar; Lalitha Shankar; Jan Bogaerts; Alice Chen; Janet Dancey; Wendy Hayes; F Stephen Hodi; Otto S Hoekstra; Erich P Huang; Nancy Lin; Yan Liu; Patrick Therasse; Jedd D Wolchok; Elisabeth de Vries
Journal:  Eur J Cancer       Date:  2016-05-26       Impact factor: 9.162

Review 5.  Pitfalls in RECIST Data Extraction for Clinical Trials: Beyond the Basics.

Authors:  Richard G Abramson; Carrie R McGhee; Nikita Lakomkin; Carlos L Arteaga
Journal:  Acad Radiol       Date:  2015-03-18       Impact factor: 3.173

6.  C-reactive protein as a marker of melanoma progression.

Authors:  Shenying Fang; Yuling Wang; Dawen Sui; Huey Liu; Merrick I Ross; Jeffrey E Gershenwald; Janice N Cormier; Richard E Royal; Anthony Lucci; Christopher W Schacherer; Julie M Gardner; John D Reveille; Roland L Bassett; Li-E Wang; Qingyi Wei; Christopher I Amos; Jeffrey E Lee
Journal:  J Clin Oncol       Date:  2015-03-16       Impact factor: 44.544

Review 7.  Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.

Authors:  Robert H El-Maraghi; Elizabeth A Eisenhauer
Journal:  J Clin Oncol       Date:  2008-02-19       Impact factor: 44.544

8.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

9.  RECIST 1.1-Update and clarification: From the RECIST committee.

Authors:  Lawrence H Schwartz; Saskia Litière; Elisabeth de Vries; Robert Ford; Stephen Gwyther; Sumithra Mandrekar; Lalitha Shankar; Jan Bogaerts; Alice Chen; Janet Dancey; Wendy Hayes; F Stephen Hodi; Otto S Hoekstra; Erich P Huang; Nancy Lin; Yan Liu; Patrick Therasse; Jedd D Wolchok; Lesley Seymour
Journal:  Eur J Cancer       Date:  2016-05-14       Impact factor: 9.162

10.  Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the European Lung Cancer Working Party.

Authors:  M Paesmans; J P Sculier; P Libert; G Bureau; G Dabouis; J Thiriaux; J Michel; O Van Cutsem; R Sergysels; P Mommen; J Klastersky
Journal:  Eur J Cancer       Date:  1997-12       Impact factor: 9.162

View more
  5 in total

1.  The effect of lithium on the progression-free and overall survival in patients with metastatic differentiated thyroid cancer undergoing radioactive iodine therapy.

Authors:  Hongxiu Luo; Andrew Tobey; Sungyoung Auh; Craig Cochran; Marina Zemskova; James Reynolds; Cristiane Lima; Kenneth Burman; Leonard Wartofsky; Monica Skarulis; Electron Kebebew; Joanna Klubo-Gwiezdzinska
Journal:  Clin Endocrinol (Oxf)       Date:  2018-08-13       Impact factor: 3.478

2.  The value of DWI in predicting the response to synchronous radiochemotherapy for advanced cervical carcinoma: comparison among three mathematical models.

Authors:  Hui Zhang; Yuyang Zhou; Jie Li; Pengjuan Zhang; Zhenzhen Li; Junwu Guo
Journal:  Cancer Imaging       Date:  2020-01-14       Impact factor: 3.909

3.  Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy ± immune checkpoint inhibition.

Authors:  Marcus Unterrainer; Julian Taugner; Lukas Käsmann; Amanda Tufman; Niels Reinmuth; Minglun Li; Lena M Mittlmeier; Peter Bartenstein; Wolfgang G Kunz; Jens Ricke; Claus Belka; Chukwuka Eze; Farkhad Manapov
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-10-19       Impact factor: 9.236

4.  iRECIST-based versus non-standardized free text reporting of CT scans for monitoring metastatic renal cell carcinoma: a retrospective comparison.

Authors:  Laura Schomburg; Amer Malouhi; Marc-Oliver Grimm; Maja Ingwersen; Susan Foller; Katharina Leucht; Ulf Teichgräber
Journal:  J Cancer Res Clin Oncol       Date:  2022-04-14       Impact factor: 4.322

5.  The utility of low-iodine diet in preparation for thyroid cancer therapy with radioactive iodine-A cohort study.

Authors:  Hongxiu Luo; Andrew Tobey; Sungyoung Auh; Craig Cochran; Noha Behairy; Maria Merino; Marina Zemskova; Joanna Klubo-Gwiezdzinska
Journal:  Front Pharmacol       Date:  2022-09-30       Impact factor: 5.988

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.